SOURCE: Upstream Biosciences Inc.

February 05, 2007 13:39 ET

Upstream Biosciences Inc. Taps Libby Communications, Inc. as Public Relations Agency of Record

VANCOUVER, BC -- (MARKET WIRE) -- February 5, 2007 -- Upstream Biosciences Inc. (OTCBB: UPBS) ("Upstream" or the "Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has named Libby Communications, Inc. as its public relations agency of record.

"David Libby has a track record of success representing me and Dexster Smith, Upstream's Co-founder and President. Thanks to David, Dexster and I have been covered by CNN, ABC Nightly News, CNBC, Fortune, Forbes, Wall Street Journal, New York Times, Wired, Business 2.0, and Der Spiegel, among many others," states CEO Joel Bellenson. "Libby Communications is the right strategic partner to help market our recent successes."

"Upstream Biosciences is clearly a company with promise," adds David Libby, Principal, Libby Communications, Inc. "The corporate leadership is strong and the future of genetic diagnostics is bright in today's technologically advanced world. I am again looking forward to working with the talented professionals and telling their new story of innovation and advancement."

For more information, please contact Samantha Haynes, investor relations at 1-800-539-0289 or info@upstreambio.com.

Media Contact:

David Libby at 510.868.4903 or cell 510.377.1466 or dlibby@libbycommunnications.com

About Upstream Biosciences Inc.

Upstream Biosciences Inc. is an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response founded in 2004. Upstream discovers, develops, and licenses genetic based diagnostics for cancer susceptibility and drug response. Upstream's proprietary data mining pipeline enables it to locate and analyze genetic variations in the regions of DNA 'upstream' of the gene, the 'gene switches,' which control the quantities and timing of expression of the genes, and proteins important to disease and drug response. For more information about the Company please visit http://www.upstreambio.com.

About Libby Communications, Inc.

Libby Communications, Inc. builds big public relations for growing technology companies. Since 2001, the company has helped business-to-business clients in various sectors assemble and execute public relations campaigns for sustained growth and activity. Libby Communications, Inc. is headquartered in Oakland, California. For more information about the company, please visit http://www.libbycommunications.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) the Company may become an emerging leader in the field of diagnostics for cancer and the prediction of drug response; (ii) Libby Communications can help market the Company's recent successes; (iii) the future of genetic diagnostics is favorable; (iv) the Company may discover, develop and license its genetic based diagnostics for cancer susceptibility and drug response; and (v) the Company's data mining pipeline may enable the Company to locate and analyze genetic variations in the regions of DNA which control the quantities and timing of expression of the genes and proteins important to disease and drug response. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that the Company does not execute its business plan; (ii) the inability of the Company to keep pace with technological advancements in the field of genetic diagnostics; (iii) the Company's inability to adequately protect its intellectual property or the Company's inadvertent infringement of third party intellectual property; (iv) the Company not being able to retain key employees; (v) competitors providing better or cheaper products and technologies; (vi) markets for the Company's products not developing as expected; (vii) the Company's inability to finance its operations or growth; (viii) inability to obtain all necessary government and regulatory approvals; and (ix) the inability to effectively market and commercialize the Company's technologies, including the establishment of viable relationships with third parties. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.

Contact Information

  • Media Contact:
    David Libby
    510.868.4903
    cell 510.377.1466
    Email Contact